Trabectedin Enhances Oncolytic Virotherapy by Reducing Barriers to Virus Spread and Cytotoxic Immunity in Preclinical Pediatric Bone Sarcoma
Emily M. Ringwalt, Mark A. Currier, Andrea M. Glaspell, Chun‐Yu Chen, Matthew V. Cannon, Maren Cam, Amy C. Gross, Matthew J. Gust, Pin-Yi Wang, Louis Boon, Laura E. Biederman, Emily J. Schwarz, Prajwal Rajappa, Dean Anthony Lee, Elaine R. Mardis, , Timothy P. Cripe
This study shows trabectedin enhances oncolytic virotherapy by reducing anti-viral barriers and boosting immune-mediated tumor regression in preclinical models.
Molecular Therapy Oncology · Sep 26, 2024Peer-reviewedCancer Biology